FisherVista

GeoVax Labs reported a net loss of $5.3 million for Q1 2026 and provided updates on its GEO-MVA mpox/smallpox vaccine, which is advancing toward a Phase 3 immunobridging study under an EMA-aligned expedited pathway, addressing global supply constraints and biodefense priorities.

BioStem Technologies reported first quarter 2026 net revenue of $6.1 million, a shift toward hospital market focus following the BioTissue assets acquisition, and progress toward a planned Nasdaq uplisting.

Aemetis reported improved financials in 1Q26, with revenue up 27% and gross profit turning positive, driven by recurring 45Z credit recognition and expanding RNG volumes.

HeartBeam reported first-quarter 2026 results highlighting the launch of commercial partnerships and progress in heart attack detection initiatives, with a reduced net loss of $4.7 million.

BOXABL and FG Merger II Corp. announced SEC effectiveness of their S-4 registration, setting shareholder meetings for June 9, 2026, to approve the business combination that would take BOXABL public on Nasdaq under ticker BXBL.

BluSky AI Inc. is accelerating deployment of its SkyMod modular data centers to meet surging demand for high-performance AI computing, positioning its Distributed Neocloud model as a solution to infrastructure capacity constraints.

American Fusion Inc. has completed the structural frame for its 5MW Texatron fusion system, advancing toward integrated assembly and testing as the company scales up for commercial deployment.

Crypto asset investment products attracted nearly $860 million in fresh capital last week, marking six straight weeks of positive flows as optimism over proposed U.S. regulation continues to influence market sentiment.

Microsoft is considering delaying or scrapping its 2030 goal to match hourly power consumption with clean energy purchases due to growing AI energy demands, highlighting the tension between tech expansion and climate commitments.

The disruption in the Strait of Hormuz is endangering the global electric vehicle industry by blocking transport of critical raw materials for batteries, risking production slowdowns and higher consumer prices.

The Department of Health and Human Services plans to ease safeguards for AI healthcare tools, sparking debate over the balance between innovation and patient safety.

Dogwood Therapeutics announced Q1 2026 financial results and highlighted progress in its non-opioid pain pipeline, including Phase 2b data for Halneuron expected in fall 2026 and FDA clearance for SP16 to enter Phase 1b.

LIG Assets, Inc. is working on a technical report under SEC Regulation S-K Subpart 1300 to update the valuation of its calcium carbonate mining assets in Marianna, Florida, which were previously appraised at $400 million in 2009, aiming to reflect substantial market changes and enhance transparency.

BluSky AI Inc. announced a Regulation A+ offering to raise funds for expanding its modular AI Factory footprint and Neocloud compute capacity across the United States, allowing individual and accredited investors to participate with a minimum investment of $1,000.

Aditxt (NASDAQ: ADTX) will implement a 1-for-27 reverse stock split on May 18, 2026, to meet Nasdaq’s minimum bid price requirement, reducing outstanding shares from 13.8 million to about 510,123.

SPARC AI Inc. is featured in an AINewsWire editorial discussing its software-only platform that enables drones to navigate and target without GPS, addressing critical defense needs in contested electronic warfare environments.

MindBio Therapeutics Corp. is developing an AI-driven voice analysis platform to detect drug and alcohol impairment from brief speech recordings, addressing growing demand for noninvasive, scalable intoxication detection in healthcare, workplace safety, and public health.

CNS Pharmaceuticals (NASDAQ: CNSP) reported first-quarter 2026 financial results and detailed a strategic transformation toward acquiring clinical-stage neurology and oncology assets, supported by a $22.5 million private placement to fund operations and potential acquisitions.

Kairos Pharma receives the 2026 GHP Magazine Healthcare & Pharmaceutical Award for its work in developing cancer therapies that overcome drug resistance, highlighting its lead candidate ENV-105 currently in clinical trials.